Translate this website into the following languages:

Close Tab
UC San Diego Health
menu iconMenu
search iconSearch

UC San Diego Moores Cancer Center Offers New Hope for Deadly Brain Tumor


February 03, 2012  |  

One of few clinical trial sites, worldwide

Jim Black is fighting the meanest, most aggressive, most common kind of brain tumor in the United States: recurrent glioblastoma multiforme (GBM).  In the United States, each year, approximately 10,000 patients are affected by GBM.  Now, a novel investigational device – available only at clinical trial sites – is offering new hope to these patients.

The non-invasive procedure – called Tumor Treating Fields (TTF) – is delivered using a portable device – called the NovoTTF-100A System made by Novocure.  The TTF procedure uses alternating electrical fields to disrupt the rapid cell division exhibited by cancer cells. 

 Santosh Kesari
Santosh Kesari, MD, PhD, director of Neuro-Oncology at UC San Diego Moores Cancer Center.
“Patients with recurrent GBM present a significant treatment challenge,” said Santosh Kesari, MD, PhD, director of Neuro-Oncology at UC San Diego Moores Cancer Center.  “The initial clinical research for the approval trial demonstrated that, compared to patients who were treated with chemotherapy, patients treated with NovoTTF achieved comparable survival times, had fewer side effects, and reported improved quality of life.”


On average, a patient with GBM survives less than 15 months with optimal treatment and only three to five months without additional effective treatment.  The TTF procedure may provide physicians with a fourth treatment option in addition to surgery, radiation therapy and chemotherapy.

TTFs inhibit tumor growth by causing cancerous cells to die.  The TTF procedure is delivered using non-invasive, insulated transducer arrays (electrodes) that are placed directly on the skin in the region of the tumor.  The hat-like collection of electrodes connects to a portable device which is slightly thicker than a laptop and weighs about six pounds.  The device sends a low intensity, alternating electric field into the tumor which prevents the cells from dividing and spreading and causes cancer cells to die. 

The most commonly reported side effect from NovoTTF is a mild-to-moderate scalp rash, beneath the electrodes.  The FDA-approved device is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

“When all other options have been exhausted, patients are willing to do just about anything to keep the tumor at bay,” said Kesari.  “This device gives them an opportunity to fight back, to feel like they are taking an active, hands-on role in their own treatment, and provides tremendous hope.”

# # #

Media Contact: Kim Edwards, 619-543-6163,

Related Specialties

Media Contact

Share This Article

Related News

While astronauts on long space missions do not experience a change in spinal disc height, the muscles supporting the spine weaken, find researchers at University of California San Diego School of Medi ...
There are many unanswered questions about the mechanisms that contribute to the onset of type 1 diabetes. Researchers at University of California San Diego School of Medicine hope to answer some of th ...
Viruses hijack the molecular machinery in human cells to survive and replicate, often damaging those host cells in the process. Researchers at the University of California San Diego School of Medicine ...
Although only 10 percent of amyotrophic lateral sclerosis (ALS) cases are hereditary, a significant number of them are caused by mutations that affect proteins that bind RNA, a type of genetic materia ...

Follow Us

Our bimonthly newsletter delivers healthy lifestyle tips, patient stories and research discovery news. Subscribe: